AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Go back to AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
AbbVie (NYSE: ABBV) Delayed: 115.78 +1.88 (1.65%)
Previous Close $113.90    52 Week High $68.12 
Open $115.17    52 Week Low $50.71 
Day High $116.28    P/E 25.11 
Day Low $113.95    EPS $4.61 
Volume 7,025,265